More News

22 Jan 2018 Sanofi to Acquire Bioverativ for $11.6 Billion
19 Jan 2018 Historic Deal Signed Between Panacea Biotec and Serum Institute of India
19 Jan 2018 Eisai enters into licensing agreement with Adlai Nortye for potential anticancer agent E7046 (prostaglandin E2 receptor type 4 antagonist)
18 Jan 2018 Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars
18 Jan 2018 X-Chem Enters Expanded Global Drug Discovery and Technology Transfer Collaboration with AstraZeneca
16 Jan 2018 Feldan Therapeutics and Green Cross LabCell Announce Start of Joint collaboration
11 Jan 2018 Adapsyn Bioscience Completes Financing to Advance its Small Molecule Natural Product Platform and Pipeline; Announces Research Collaboration with Pfizer Inc.
09 Jan 2018 Scancell to collaborate with BioNTech to investigate T cell receptor based therapeutics for the treatment of cancer
09 Jan 2018 Harbour BioMed Enters Agreement to Develop Fully Human Antibody Fragments for Innovative CAR-T Therapy
09 Jan 2018 Mallinckrodt Will Sell RECOTHROM® And PREVELEAK® To Baxter
09 Jan 2018 Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific Antibodies
09 Jan 2018 Incyte and Syros Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms
09 Jan 2018 Alder BioPharmaceuticals® Enters into European Patent Settlement and Global License Agreement with Teva in the Field of Anti-CGRP-Based Therapy
08 Jan 2018 Imcyse announces a research collaboration with Pfizer Inc. in rheumatoid arthritis (RA)
08 Jan 2018 Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies
08 Jan 2018 Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance
08 Jan 2018 Novo Nordisk has proposed to acquire Ablynx for upto €30.50 per share in cash, consisting of €28.00 upfront and €2.50 in Contingent Value Rights
08 Jan 2018 Cypralis and Gilead Sciences, Inc. agree on license terms under which Cypralis will hold exclusive development and commercialisation rights to certain jointly-owned ‘cyprolides’ for acute and chronic degenerative diseases
07 Jan 2018 Potenza Therapeutics Unveils Pipeline of Immuno-Oncology Programs
07 Jan 2018 Jiangsu Hengrui Medicine and Arcutis Announce a Development and Commercialization Partnership for Novel Immune-Mediated Dermatology Therapy Using SHR0302
07 Jan 2018 Rebiotix and CoreBiome Collaborate on Evaluating Microbiomes of Patients Treated with Microbiota Restoration Therapy™
07 Jan 2018 Retrophin and Censa Pharmaceuticals Enter into Strategic Collaboration to Advance CNSA-001 for the Treatment of Phenylketonuria (PKU)
07 Jan 2018 KBP Biosciences Raises $76 Million in Series A Financing and Appoints Brian P. McVeigh as Chief Executive Officer
05 Jan 2018 Takeda and Denali Therapeutics Collaborate to Develop and Commercialize Therapies for Neurodegenerative Diseases
05 Jan 2018 Takeda Announces Intention to Acquire TiGenix

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up